2022年度妇科肿瘤诊治进展

doi:10.19401/j.cnki.1007-3639.2023.01.002

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (1): 14-24.doi: 10.19401/j.cnki.1007-3639.2023.01.002

2022年度妇科肿瘤诊治进展

郭勤浩(), 余敏, 吴小华()

复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2023-01-03 修回日期:2023-01-12 出版日期:2023-01-30 发布日期:2023-02-13
通信作者: 吴小华（ORCID: 0000-0002-6889-3541），博士，主任医师，复旦大学附属肿瘤医院妇瘤科主任。
作者简介:郭勤浩（ORCID: 0000-0003-4661-481X），博士，主治医师。
吴小华，医学博士，教授，博士研究生导师。现任复旦大学附属肿瘤医院妇瘤科主任、妇科肿瘤多学科综合治疗组首席专家，上海市优秀学科带头人、上海市医学领军人才。现任中国抗癌协会妇科肿瘤专业委员会主任委员、中国临床肿瘤学会理事、上海市抗癌协会常务理事及妇科肿瘤专业委员会前任主任委员。曾任国际妇科癌症学会教育委员会委员、亚太地区理事候选人、美国妇科肿瘤学会国际委员会委员、美国西北大学医学院妇产科学系兼职教授等。目前还担任International Journal of Gynecological Cancer、Cancer Medicine、Journal of Gynecological Oncology、《中华妇产科杂志》、《中华解剖与临床杂志》、《中国癌症杂志》等杂志编委；美国NCCN宫颈癌和子宫内膜癌资源分层诊疗（NCCN Framework）临床指南审阅专家。

Progress in diagnosis and treatment of gynecological tumors in 2022

GUO Qinhao(), YU Min, WU Xiaohua()

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2023-01-03 Revised:2023-01-12 Published:2023-01-30 Online:2023-02-13
Contact: WU Xiaohua

摘要/Abstract

摘要：

2022年，国家癌症中心发布的最新数据显示，中国妇科肿瘤的发病率呈上升趋势，以卵巢癌为例，年新发病例数为57 200例，粗发病率为8.47/10万，年死亡病例数为27 200例，粗死亡率达4.04/10万，发病率和死亡率均高于世标率（分别为5.59/10万和2.45/10万），中国从事妇科肿瘤防治事业的医师面临更大的挑战。妇科肿瘤在早期经过规范性治疗后整体疗效较好，但对于晚期、复发转移的患者，有限的治疗模式及高复发率往往导致预后较差。近年来，靶向治疗、免疫治疗、抗体药物偶联物治疗等新兴治疗方式开创了妇科肿瘤治疗的新纪元，为妇科肿瘤患者带来了更多治疗希望。本文总结2022年度妇科肿瘤手术治疗、放疗、化疗、靶向治疗、免疫治疗和生物标志物检测等方面的重大进展，以期更好地指导妇科肿瘤个体化精准治疗。

关键词: 宫颈癌, 卵巢癌, 子宫内膜癌, 外阴癌, 诊治进展

Abstract:

In 2022, the National Cancer Center released the latest data. The results show that the incidence of gynecologic tumors in China shows an upward trend. Taking ovarian cancer as an example, the annual number of new cases is 57 200, with a crude incidence rate of 8.47/100 000, and the annual number of death cases is 27 200, with a crude mortality rate of 4.04/100 000, and the morbidity and mortality are higher than the world standard rates (5.59/100 000 and 2.45/100 000, respectively). Physicians practicing gynecologic oncology in China face greater challenges. Patients with early gynecologic tumors have better overall outcomes after standardized treatment. However, limited treatment modalities and high recurrence rates often lead to poorer prognosis for patients with advanced, recurrent or metastatic gynecologic malignancies. In recent years, emerging treatments such as targeted therapy, immunotherapy and antibody-drug conjugate have ushered in a new era in the treatment of gynecologic tumors, bringing more hope to patients. This article summarized the significant advances in gynecological tumor surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy and biomarkers in the past year, so as to better guide the individualized and precise treatment of gynecologic tumors.

Key words: Cervical cancer, Ovarian cancer, Endometrial cancer, Vulvar cancer, Progress in diagnosis and treatment

中图分类号:

R737.3

郭勤浩, 余敏, 吴小华. 2022年度妇科肿瘤诊治进展[J]. 中国癌症杂志, 2023, 33(1): 14-24.

GUO Qinhao, YU Min, WU Xiaohua. Progress in diagnosis and treatment of gynecological tumors in 2022[J]. China Oncology, 2023, 33(1): 14-24.

参考文献 53

[1]	RAMIREZ P T, FRUMOVITZ M, PAREJA R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer[J]. N Engl J Med, 2018, 379(20): 1895-1904. doi: 10.1056/NEJMoa1806395
[2]	RAMIREZ P, FRUMOVITZ M, PAREJA R, et al. Open vs. Minimally Invasive Radical Hysterectomy in Early Cervical Cancer: LACC Trial Final Analysis (LBA 10)[J]. Gynecol Oncol, 2022, 166: S53-S54. doi: 10.1016/S0090-8258(22)01302-6
[3]	National Comprehensive Cancer Network. NCCN Guidelines for treatment of cervical cancer[J]. (2017-05-15)[2022-12-20]. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.
[4]	CIBULA D, KÖHLER C, BAJSOVÁ S, et al. 526MO Pathological assessment of sentinel lymph node in early-stage cervical cancer: results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)[J]. Ann Oncol, 2022, 33: S786.
[5]	CHEN J, LI K, HAN Y, et al. 560P Neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced cervical cancer (NACI): a prospective, single-arm, phase Ⅱ trial[J]. Ann Oncol, 2022, 33: S804. doi: 10.1016/j.annonc.2022.07.688
[6]	MAYADEV J, ZAMARIN D, DENG W, et al. Safety and immunogenicity of Anti PD-L1 (atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: an NRG Oncology trial (024)[J]. Gynecol Oncol, 2022, 166: S18-S19.
[7]	Rodrigues M, Loap P, Dubot C, et al. 2022. Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial [J]. American Society of Clinical Oncology.
[8]	XIAO Y, CHENG H, WANG L, et al. 562P Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: preliminary results of a single-arm, open-label, phase Ⅱ trial[J]. Ann Oncol, 2022, 33: S805.
[9]	MONK B, TOITA T, WU X H, et al. Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled CALLA trial[R]. Oral Abstracts (Regular and Late-Breaking Submission). BMJ Publishing Group Ltd, 2022.
[10]	NASIOUDIS D, RAMIREZ P T. 2022 Society of Gynecologic Oncology meeting report[J]. Int J Gynecol Cancer, 2022. [Online ahead of print]
[11]	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer. Version 1. 2022[EB/OL]. [2022-12-20]. https://www.nccn.org/professionals/physician_gls/pdf/cervical.
[12]	NODA K, TESHIMA K, IKEDA M, et al. Phase Ⅱ study of UFT in cancer of the uterine cervix[J]. Gan To Kagaku Ryoho, 1985, 12(4): 900-906.
[13]	NODA K, OHASHI Y, SUGIMORI H, et al. Phase Ⅲ double-blind randomized trial of radiation therapy for stage Ⅲb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better[J]. Gynecol Oncol, 2006, 101(3): 455-463. doi: 10.1016/j.ygyno.2005.11.006
[14]	FUJIWARA K, NISHIO S, YAMAMOTO K, et al. LBA31 Randomized phase Ⅲ trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial[J]. Ann Oncol, 2022, 33: S1398.
[15]	TEWARI K S, COLOMBO N, MONK B J, et al. Pembrolizumab+chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: subgroup analysis of KEYNOTE-826[M]. American Society of Clinical Oncology, 2022.
[16]	MONK B, TEWARI K, DUBOT C, et al. Patient-reported outcomes from the phase 3 randomized, double-blind, KEYNOTE-826 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (023)[J]. Gynecol Oncol, 2022, 166: S18.
[17]	LORUSSO D, VERGOTE I, O’CEARBHAILL R E, et al. Tisotumab vedotin (TV)+ pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): interim results of ENGOT Cx8/GOG 3024/innovaTV 205[M]. American Society of Clinical Oncology, 2022.
[18]	OAKNIN A, MOORE K N, MEYER T, et al. 520MO Safety and efficacy of nivolumab (NIVO)±ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358[J]. Ann Oncol, 2022, 33: S782. doi: 10.1016/j.annonc.2022.07.648
[19]	WANG J, LOU H M, CAI H B, et al. A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC)[J]. J Clin Oncol, 2022, 40(16_suppl): 106.
[20]	AN J S, WU L Y, LI X M, et al. Efficacy and safety of serplulimab (an anti-PD-1 antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy (074)[J]. Gynecol Oncol, 2022, 166: S47.
[21]	TEWARI K S, MONK B J, VERGOTE I, et al. Survival with cemiplimab in recurrent cervical cancer[J]. N Engl J Med, 2022, 386(6): 544-555. doi: 10.1056/NEJMoa2112187
[22]	XU Q, WANG J J, SUN Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase Ⅱ trial[J]. J Clin Oncol, 2022, 40(16): 1795-1805.
[23]	ZHENG M, Y ZHOU, ZHOU J, et al. 564P Efficacy and safety of tislelizumab plus anlotinib in the treatment of cervical cancer resistant to standard therapy: a prospective, single-arm, open labelled phase Ⅱ clinical trial[J]. Ann Oncol, 2022, 33: S806.
[24]	OAKNIN A, BACKES F, VAN NIEUWENHUYSEN E, et al. LIO-1: initial phase 2 experience of lucitanib+nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034)[J]. Gynecol Oncol, 2022, 166: S24.
[25]	XIA L F, ZHOU Q, GAO Y N, et al. A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma[J]. Nat Commun, 2022, 13(1): 7581. doi: 10.1038/s41467-022-35133-4 pmid: 36481736
[26]	O’MALLEY D M, NEFFA M, MONK B J, et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phaseⅡ study[J]. J Clin Oncol, 2022, 40(7): 762-771. doi: 10.1200/JCO.21.02067
[27]	WU X H, JI J F, LOU H M, et al. Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase Ⅱ trial (075)[J]. Gynecol Oncol, 2022, 166: S47-S48.
[28]	SIVARS L, HELLMAN K, CRONA GUTERSTAM Y, et al. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer[J]. Gynecol Oncol, 2022, 167(1): 107-114. doi: 10.1016/j.ygyno.2022.07.028 pmid: 35918201
[29]	NORPPA N, STAFF S, HELMINEN M, et al. Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: results from a tertiary referral center[J]. Gynecol Oncol, 2022, 165(3): 478-485. doi: 10.1016/j.ygyno.2022.03.023 pmid: 35397919
[30]	TANYI J L, RANDALL L M, CHAMBERS S K, et al. A phase Ⅲ study of pafolacianine injection (OTL38) for intraoperative imaging of folate receptor-positive ovarian cancer (study 006)[J]. J Clin Oncol, 2023, 41(2): 276-284. doi: 10.1200/JCO.22.00291
[31]	SEHOULI J, FOTOPOULOU C, VERGOTE I, et al. Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: a subanalysis of the DESKTOP Ⅲ trial[J]. J Clin Oncol, 2022, 40(16_suppl): 5520. doi: 10.1200/JCO.2022.40.16_suppl.5520
[32]	LECURU F, SEHOULI J, VERGOTE I B, et al. 573P Role of CA125 in patients included in the DESKTOP Ⅲ/ENGOT-ov20 trial[J]. Ann Oncol, 2022, 33: S809.
[33]	ZHOU D C, LIU J H, LIU R H, et al. Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency (NANT): study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study[J]. Front Oncol, 2022, 12: 852772. doi: 10.3389/fonc.2022.852772
[34]	LIM M C, CHANG S J, PARK B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial[J]. JAMA Surg, 2022, 157(5): 374-383. doi: 10.1001/jamasurg.2022.0143
[35]	FILIS P, MAURI D, MARKOZANNES G, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials[J]. ESMO Open, 2022, 7(5): 100586. doi: 10.1016/j.esmoop.2022.100586
[36]	FUJIWARA K, KRISTELEIT R, GHAMANDE S, et al. 178O Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase Ⅲ ATHENA-MONO study[J]. Ann Oncol, 2022, 33: S1505-S1506. doi: 10.1016/j.annonc.2022.10.214
[37]	DISILVESTRO P, BANERJEE S, COLOMBO N, et al. 517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial[J]. Ann Oncol, 2022, 33: S779. doi: 10.1016/j.annonc.2022.07.645
[38]	RAY-COQUARD I L, LEARY A, PIGNATA S, et al. LBA29 Final overall survival (OS) results from the phase Ⅲ PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)[J]. Ann Oncol, 2022, 33: S1396-S1397.
[39]	GAO Q L, ZHU J Q, ZHAO W D, et al. Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer: phase Ⅲ trial (L-MOCA)[J]. Clin Cancer Res, 2022, 28(11): 2278-2285. doi: 10.1158/1078-0432.CCR-21-3023
[40]	GSK. GSK provides an update on Zejula (niraparib) US prescribing information[EB/OL]. (2022-11-11)[2022-12-20]. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-an-update-on-zejula-niraparib-us-prescribing-information/.
[41]	MIRZA M, WU X, ZHU J, et al. VP7-2022: an ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): a double-blind, randomized, placebo-controlled, phase Ⅲ trial[J]. Ann Oncol, 2022. [Online ahead of print]
[42]	KRISTELEIT R, OZA A M. Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations-authors’ reply[J]. Lancet Oncol, 2022, 23(7): e315. doi: 10.1016/S1470-2045(22)00343-6
[43]	MATULONIS U, LORUSSO D, OAKNIN A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study (LBA 4)[J]. Gynecol Oncol, 2022, 166: S50.
[44]	COLOMBO N, VAN GORP T, MATULONIS U A, et al. Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer[J]. J Clin Oncol, 2022, 40(17_suppl): LBA5503. doi: 10.1200/JCO.2022.40.17_suppl.LBA5503
[45]	O’MALLEY D, BARIANI G M, CASSIER P A, et al. 546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: long-term follow-up results from KEYNOTE-158[J]. Ann Oncol, 2022, 33: S796-S797.
[46]	TINKER A V, POTHURI B, GILBERT L, et al. 548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study[J]. Ann Oncol, 2022, 33: S798-S799. doi: 10.1016/j.annonc.2022.07.676
[47]	MAKKER V, COLOMBO N, CASADO HERRAEZ A, et al. 525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): study 309/KEYNOTE-775[J]. Ann Oncol, 2022, 33: S785-S786. doi: 10.1016/j.annonc.2022.07.653
[48]	WU X, LIANG S, CHEN X, et al. 555P TQB2450 injection combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent or metastatic endometrial cancer: a multicohort, open label, multicenter phase Ⅱ clinical trial - The TQB2450-Ⅱ-08 trial[J]. Ann Oncol, 2022, 33: S802.
[49]	BRADLEY W H, HAYES M P, TAYLOR N, et al. An open label, nonrandomized, multisite phase Ⅱ trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer[M]. American Society of Clinical Oncology, 2022.
[50]	TAN D S, KIM Y M, LIM M C, et al. 101P Real-world prevalence of MSI-H/dMMR across 6 different tumor types in Asia[J]. Ann Oncol, 2022, 33: S585.
[51]	ZHANG Q, MA X, CAO W, et al. 558P Molecular subtyping endometrial carcinoma in Chinese population applying an NGS-based classifier and its association with prognosis[J]. Ann Oncol, 2022, 33: S803.
[52]	SIEGENTHALER F, TEIEN LANDE K, KRAKSTAD C, et al. 589P Circulating tumour DNA as prognostic factor in endometrial cancer: updated results from an international multicenter study[J]. Ann Oncol, 2022, 33: S816.
[53]	SHAPIRA-FROMMER R, MILESHKIN L, MANZYUK L, et al. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study[J]. Gynecol Oncol, 2022, 166(2): 211-218. doi: 10.1016/j.ygyno.2022.01.029

2022年度妇科肿瘤诊治进展

Progress in diagnosis and treatment of gynecological tumors in 2022

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 53

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庞怡, 吴春晓, 顾凯, 鲍萍萍, 王春芳, 施亮, 龚杨明, 向詠梅, 窦剑明, 吴梦吟, 付晨, 施燕. 2016年上海市子宫颈癌发病和死亡情况与2002—2016年的变化趋势分析[J]. 中国癌症杂志, 2022, 32(6): 519-526.
[2]	王春桃, 葛安兴, 吴红雁, 张学艳, 杨圣, 袁红香, 程艳萍, 冯延璐, 陆欣苑, 梁戈玉. 不同级别子宫颈病变与lncRNA HOTTIP和H19单核苷酸多态性的关系研究[J]. 中国癌症杂志, 2022, 32(4): 324-334.
[3]	冯征, 温灏. 预防性输卵管卵巢切除术在遗传性卵巢癌中的应用[J]. 中国癌症杂志, 2022, 32(11): 1044-1048.
[4]	赵明明, 王天佑, 王超. 妇科恶性肿瘤术后激素替代治疗的研究进展[J]. 中国癌症杂志, 2022, 32(11): 1098-1104.
[5]	方艳惠, 马彩娟, 张纯丽, 翟嘉威, 朱巧英, 刘茵, 赵喜娃. miR-496通过SFMBT1抑制子宫颈癌HeLa细胞增殖、迁移和侵袭的相关研究[J]. 中国癌症杂志, 2021, 31(8): 697-703.
[6]	龙行涛, 周琦, 王冬, 陈月梅, 金福军 . 子宫颈癌2018年FIGO新分期ⅢC期患者预后分析[J]. 中国癌症杂志, 2021, 31(8): 725-733.
[7]	雷雅洁, 高　毅, 王治洁, 程　玺, 杨雨菲, 周宏宇, 陈丽华, 陈伊新, 李浩然, 李子庭, 吴小华 . 早期卵巢癌（Ⅰ C ~ⅡA）患者腹主动脉旁淋巴结清扫术对预后影响的临床分析[J]. 中国癌症杂志, 2021, 31(8): 740-745.
[8]	中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南（2021年版）[J]. 中国癌症杂志, 2021, 31(6): 474-489.
[9]	中国抗癌协会妇科肿瘤专业委员会. 子宫内膜癌诊断与治疗指南（2021年版）[J]. 中国癌症杂志, 2021, 31(6): 501-512.
[10]	董诗洁, 胡晓欣, 王　葳, 杨　孟, 岳　磊, 童　彤, 顾雅佳. 基于多序列MRI与多体系影像组学模型预测子宫颈癌淋巴结转移的研究[J]. 中国癌症杂志, 2021, 31(6): 460-467.
[11]	朱　俊, 吴小华. 2020年度妇科恶性肿瘤最新研究进展及展望[J]. 中国癌症杂志, 2021, 31(4): 250-256.
[12]	蔡树模, 汤　洁, 黄　啸, 黄晓炜, 刘素萍, 柯桂好, 郑　重, 程　玺, 唐美琴. 铂类药物敏感复发卵巢癌患者的三步化疗法附20例分析[J]. 中国癌症杂志, 2021, 31(4): 330-334.
[13]	刘懿萱 , 文泽轩 , 郭　林 , 卢仁泉 . TTK1在卵巢癌铂类耐药中的生物学功能分析[J]. 中国癌症杂志, 2021, 31(3): 182-191.
[14]	俞　弋, 丛　青, 徐丛剑, 姜　伟. PAFR对卵巢癌细胞顺铂敏感性的影响及机制研究[J]. 中国癌症杂志, 2021, 31(11): 1063-1071.
[15]	中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会, 国家病理质控中心. 子宫内膜癌分子检测中国专家共识（2021年版）[J]. 中国癌症杂志, 2021, 31(11): 1126-1144.